Published in Medical Letter on the CDC and FDA, January 16th, 2005
The OTC 12-hour extended release Ibuprofen formulation is based on SCOLR Pharma's proprietary and patented CDT drug delivery platform. There are currently no extended release formulations of Ibuprofen approved for use in North America.
SCOLR's IND seeks permission from the FDA to begin a U.S. human study intended to support future product approval. The FDA requires a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA